CMAC’s vision is to revolutionise the way pharmaceuticals and high value products are made. The approaches developed and adopted within CMAC have been developed through close collaboration with industry and the support of its Tier 1 partners, which includes GlaxoSmithKline, AstraZeneca, Bayer, Lilly, Novartis, Roche and Takeda. Established in 2011, the CMAC has a £150m funding portfolio and currently comprises more than 130 staff and researchers, including academics, post docs, and more than 45 PhD students, as well as an experienced support team.
Press: article in The Scotsman
CMAC is featured in article in The Scotsman..... more
The Research Center Pharmaceutical Engineering and CMAC Future Manufacturing Research Hub announce strategic partnership to advance pharmaceutical manufacturing
The Research Center Pharmaceutical Engineering (RCPE) and CMAC (Continuous Manufacturing and Advanced Crystallisation) announce a new international partnership to accelerate progress in advanced manufacturing for pharmaceuticals. By combining their world-leading and, complementary expertise and facilities this partnership provides a single-source platform for accessing new product and process design knowledge..... more
Jag Srai talks to Research Horizons magazine
CMAC Hub academic Dr Jag Srai, leader of the REMEDIES Commercial Supply Chain, has an article in Research Horizons magazine and on the Cambridge website.... more